Behavioral Health Business March 11, 2024
There are currently no treatments for a genetic anomaly that causes a type of autism spectrum disorder and Phelan-McDermid syndrome (PMS), an autism-related condition.
Biotechnology company Jaguar Gene Therapy is launching the first human gene therapy trial to address the root cause of the condition.
The therapy, called JAG201, targets the SHANK3 gene. Mutations in this gene have been associated with autism.
Jaguar is a clinical-stage biotechnology company that partners with its subsidiary Advanced Medicine Partners to manufacture its therapeutics. Deerfield Management Company, ARCH Venture Partners and Eli Lilly and Company have invested in the company.
A variation on the SHANK3 gene is only one of ASD’s multiple possible causes.
The disorder can be caused by other genetic...
Today's Sponsors
Today's Sponsor